Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Compare findings

Compare selected psilocybin depression and alcohol-use reports by population, design, sample, endpoint, finding and limitations with original source links.

Free access · No subscription for research tools or data exports

Compare selected original reports

This educational comparison reuses the original annotations in our evidence guides. It is a selected set, not a systematic review or an independently clinically reviewed treatment recommendation. Source-check dates belong to the annotations and do not advance when the page is rebuilt.

Understand the measuresDepression safety and interpretationAlcohol evidence and correction links
2 selected reports. Different scales, comparators and follow-up times must not be ranked as equivalent effects.
Report and populationDesign and sampleEndpointFindingLimitations
Griffiths et al. · 2016

People with a life-threatening cancer diagnosis and depression or anxiety symptoms

Source checked 2026-10-09

Indexed record

Randomized double-blind crossover: high versus very low psilocybin dose with psychological support

51 participants

Clinician- and self-rated anxiety and depressive symptoms; randomized comparison before crossoverPre-crossover comparison favored high dose

The high-dose condition showed greater symptom reductions. Improvements were also observed at six months after both sequences had received the high dose.

The six-month observations are not a continuing untreated-control comparison. Small, screened sample; expectancy and recognizable drug effects complicate blinding.
Ross et al. · 2016

People with cancer-related anxiety and depression

Source checked 2026-10-09

Indexed record

Randomized double-blind crossover: psilocybin versus niacin, both with psychotherapy

29 participants

Anxiety and depression measures before crossover at seven weeksPre-crossover comparisons favored psilocybin

Pre-crossover comparisons favored psilocybin on the anxiety and depression measures. Later observations suggested persistence after both groups had received psilocybin.

After crossover the study cannot establish a sustained between-group causal effect. A small selected cancer population does not establish efficacy for generalized anxiety disorder.

2 reports shown